



UCB S.A. Allée de la Recherche 60, B-1070 Brussels (Belgium)

Press Release

NEW CEO OF SCHWARZ PHARMA JOINS EXECUTIVE COMMITTEE OF UCB

Brussels, December 14, 2006 – 7:00 AM (CET) – UCB today appoints Detlef Thielgen, SCHWARZ PHARMA's new Chief Executive Officer, to UCB's Executive Committee effective January 1, 2007.

Detlef Thielgen has built an impressive career with SCHWARZ PHARMA AG. Detlef has held several positions in finance and controlling, including Chief Financial Officer in the USA (1995 -1999). As General Manager Operations (1999-2002), he was responsible for the worldwide production and supply chain. Since February 1, 2002, Detlef has been a member of SCHWARZ PHARMA's Executive Board as Chief Financial Officer. On December 13, 2006, Detlef was appointed Chief Executive Officer of SCHWARZ PHARMA AG effective January 1, 2007.

UCB's Executive Committee comprises also Melanie Lee, Executive Vice President R&D, Luc Missorten, Executive Vice President Chief Financial Officer, Jean-Pierre Pradier, Executive Vice President Corporate Human Resources, Bill Robinson, Executive Vice President, Global Operations, Bob Trainor, Executive Vice President, General Counsel, and is chaired by Roch Doliveux, Chief Executive Officer.

ENQUIRIES

Jean-Christophe Donck

+32 2 559 9346

About UCB

UCB (www.ucb-group.com) is a leading global biopharmaceutical company dedicated to the research, development and commercialisation of innovative pharmaceutical and biotechnology products in the fields of central nervous system disorders, allergy/respiratory diseases, immune and inflammatory disorders and oncology – UCB focuses on securing a leading position in severe disease categories. Employing over 8,300 people in over 40 countries, UCB achieved revenue of 2.3 billion euro in 2005. UCB is listed on the Euronext Brussels Exchange. Worldwide headquarters are located in Brussels, Belgium.